Olanzapine and Facial paralysis - a phase IV clinical study of FDA data

Summary:

Facial paralysis is reported as a side effect among people who take Olanzapine (olanzapine), especially for people who are female, 10-19 old, have been taking the drug for < 1 month also take Fluoxetine, and have Stress and anxiety.

The phase IV clinical study analyzes which people have Facial paralysis when taking Olanzapine. It is created by eHealthMe based on reports of 68,588 people who have side effects when taking Olanzapine from the FDA, and is updated regularly.

What is Olanzapine?

Olanzapine has active ingredients of olanzapine. It is often used in bipolar disorder. eHealthMe is studying from 69,242 Olanzapine users. Check the latest studies of Olanzapine.

What is Facial paralysis?

Facial paralysis (loss of function of face muscle) is found to be associated with 664 drugs and 1,146 conditions by eHealthMe. Check the latest studies of Facial paralysis.

On May, 04, 2026

68,588 people reported to have side effects when taking Olanzapine.
Among them, 73 people (0.11%) have Facial paralysis.

Could Olanzapine cause Facial paralysis?

Among these 73 people:

How long have people been on Olanzapine when they have Facial paralysis? *

What is the gender of people who have Facial paralysis when taking Olanzapine? *

female: 59.68 %
male: 40.32 %

What is the age of people who have Facial paralysis when taking Olanzapine? *

What are other drugs people take besides Olanzapine? *

What are other side effects people have besides Facial paralysis? *

Mydriasis (a dilation of the pupil): 28 people, 38.36%
Confusional State: 26 people, 35.62%
Stress And Anxiety: 24 people, 32.88%
Amaurosis (partial or total blindness without visible change in the eye): 21 people, 28.77%
Areflexia (absence of a reflex): 20 people, 27.40%
Insomnia (sleeplessness): 20 people, 27.40%
Toxic Encephalopathy (a degenerative neurologic disorder caused by exposure to toxic substances): 19 people, 26.03%
Paranoia (psychotic disorder characterized by delusions of persecution with or without grandeur): 19 people, 26.03%
Hallucinations (sensations that appear real but are created by your mind): 16 people, 21.92%
Delirium (wild excitement): 14 people, 19.18%

What are the existing conditions these people have? *

Stress And Anxiety: 21 people, 28.77%
Malaria (a parasitic disease due to mosquito bite): 20 people, 27.40%
Pneumonia Mycoplasmal (mycoplasma pneumonia (mp) is a contagious respiratory infection): 16 people, 21.92%
Insomnia (sleeplessness): 6 people, 8.22%
Abnormal Behavior: 6 people, 8.22%
Sleep Disorder: 5 people, 6.85%
Leukaemia (blood or bone marrow cancer): 5 people, 6.85%
Burkitt's Lymphoma Recurrent (recurrent blood cancer): 4 people, 5.48%
Bipolar I Disorder (mood disorder that is characterized by at least one manic or mixed episode): 4 people, 5.48%
High Blood Pressure: 3 people, 4.11%

* Approximation only. Some reports may have incomplete information.

Do you take Olanzapine and have Facial paralysis?

- Check whether Facial paralysis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Olanzapine:

Olanzapine (69,242 reports)

Browse all side effects of Olanzapine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Facial paralysis:

Facial paralysis (664 drugs)

Browse all the conditions that are associated with Facial paralysis:

Facial paralysis (1,146 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Og?odek E, Szota A, Araszkiewicz A, "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment", Aust NZJ Psychiatry, 2013 Oct .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Og?odek E, Szota A, Araszkiewicz A, "Olanzapine-induced neuroleptic malignant syndrome after 10 years of treatment", Aust NZJ Psychiatry, 2013 Oct .

How the study uses the data?

The study uses data from the FDA. It is based on olanzapine (the active ingredients of Olanzapine) and Olanzapine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.